Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_assertion type Assertion NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_head.
- NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_assertion description "[Specifically, centrin 2 and centrin 3 expression levels were classified as moderate or abundant in >97% of samples in the meningioma group, 63% of astrocytomas, >83% of metastatic and pituitary tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_provenance.
- NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_assertion evidence source_evidence_literature NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_provenance.
- NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_assertion SIO_000772 23047184 NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_provenance.
- NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_assertion wasDerivedFrom befree-20150227 NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_provenance.
- NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_assertion wasGeneratedBy ECO_0000203 NP310660.RAfmsaqkdvFkfiXoJ42IInvrqj5FJMrsioF1ASA4_RVXE130_provenance.